Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New antibiotic candidate VNRX-7145 gets first safety check in humans

NCT ID NCT04243863

First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 26 times

Summary

This early-stage trial tested the safety of a new drug, VNRX-7145, in 83 healthy adults aged 18 to 45. Participants received either a single dose or multiple doses over 10 days to see how the body handles the drug and if any side effects occur. The study is complete and focused only on safety and drug levels, not on treating any disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Worldwide Clinical Trials Early Phase Services, LLC

    San Antonio, Texas, 78217, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

VNRX-7145

What could go wrong

This is an early-stage trial in healthy volunteers, not patients. It only measures safety and drug levels, not whether the drug works against any disease.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.